Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 14/20 | 0.60 |
| ▸ | TTK | P33981 | 2/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
| ▸ | CLK2 | P49760 | 1/20 | 0.51 |
| ▸ | CLK3 | P49761 | 1/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18446785 | 0.87 | CLK2 (0.62) | ITKTTKFGFR1CLK2CLK3 | |
| SCHEMBL3921587 | 0.83 | ITK (0.68) | ITKFGFR1 | |
| SCHEMBL3929306 | 0.83 | ITK (0.51) | ITKTTKFGFR1NTRK1CLK2 | |
| SCHEMBL5386440 | 0.82 | TTK (0.72) | TTKNTRK1CLK2DYRK1A | |
| SCHEMBL3932593 | 0.82 | HTR1D (0.51) | ITKTTKPDGFRBNTRK1 | |
| SCHEMBL3922430 | 0.82 | ITK (0.51) | ITKFGFR1 | |
| SCHEMBL3919763 | 0.81 | CLK2 (0.56) | ITKFGFR1PDGFRBPDGFRANTRK1 | |
| SCHEMBL3532768 | 0.81 | FGFR1 (0.61) | ITKTTKFGFR1NTRK1CLK2 | |
| SCHEMBL3919807 | 0.80 | KDR (0.52) | ITKFGFR1PDGFRBPDGFRANTRK1 | |
| SCHEMBL18495498 | 0.80 | WNT1 (0.62) | ITKCLK2CLK3DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1732938-B1 | ORGANOPHOSPHOROUS INDAZOLE DERIVATIVES AND USE THEREOF AS PROTEIN KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2009-05-06 | — | — | EP | disclosed |
| EP-1732938-B1 | ORGANOPHOSPHOROUS INDAZOLE DERIVATIVES AND USE THEREOF AS PROTEIN KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2009-05-06 | — | — | EP | disclosed |
| US-7491710-B2 | Organophosphorus derivatives of indazoles and use thereof as medicinal products | AVENTIS PHARMA S.A. (FR) | 2009-02-17 | — | — | US | disclosed |
| US-7491710-B2 | Organophosphorus derivatives of indazoles and use thereof as medicinal products | AVENTIS PHARMA S.A. (FR) | 2009-02-17 | — | — | US | disclosed |
| US-7491710-B2 | Organophosphorus derivatives of indazoles and use thereof as medicinal products | AVENTIS PHARMA S.A. (FR) | 2009-02-17 | — | — | US | disclosed |
| CN-1894264-A | Organophosphorous indazole derivatives and use thereof as protein kinase inhibitors | AVENTIS PHARMA SA (FR) | 2007-01-10 | — | — | CN | disclosed |
| US-20050137171-A1 | Novel organophosphorus derivatives of indazoles and use thereof as medicinal products | AVENTIS PHARMA S.A. (FR) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137171-A1 | Novel organophosphorus derivatives of indazoles and use thereof as medicinal products | PPIP5K2, INPPL1, IP6K3 | ITK 1443/4885TTK 3322/4885FGFR1 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.